Drug Trial Radar · NCT05168566
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
128
Planned (sponsor's estimate)
Start
Sep 1, 2022
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Teligene USIndustry
- Sponsor type
- Industry
- First posted
- Dec 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
Conditions
- Non-small Cell Lung Cancer
Interventions
Sutetinib Maleate CapsuleDrug
Study drug to be taken orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of Objective response rate (ORR)Time frame: 2 Years
Locations
31 sites in 3 countries. Site status is shown where the registry gives one.
OPN Healthcare, Inc.
Glendale, California · Recruiting
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia · Recruiting
University Cancer & Blood Center
Athens, Georgia · Recruiting
Baptist Health
Louisville, Kentucky · Withdrawn
University of Maryland Medical Center
Baltimore, Maryland · Recruiting
FirstHealth Cancer Center
Pinehurst, North Carolina · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Active not recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Macquarie University Hospital
Sydney, New South Wales, Australia · Recruiting
Sunshine Coast Hospital and Health Service
Birtinya, Queensland, Australia · Recruiting
St John of God Subiaco Hospital
Subiaco, Western Australia, Australia · Recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China · Active not recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Active not recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Active not recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Active not recruiting
Beijing Chest Hospital
Beijing, Beijing Municipality, China · Active not recruiting
The Affiliated Cancer Hospital of Chongqing University
Chongqing, Chongqing Municipality, China · Active not recruiting
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Active not recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Active not recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Active not recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Active not recruiting
Wuhan Union Hospital of China
Wuhan, Hubei, China · Active not recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Active not recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Active not recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Active not recruiting
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China · Active not recruiting
Linyi Cancer Hospital
Linyi, Shandong, China · Active not recruiting
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Active not recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Active not recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Active not recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.